Biofrontera Inc.BFRI
Price (close)
$1.18
Market cap
$17.5M
P/E
—
Revenue (TTM)
$46.2M
Net income
-$6.4M
Dividend yield
—
1-year total return
22.9%
Net margin
-13.8%
Revenue growth
17.8%
Debt / equity
—
What Biofrontera Inc. does.
manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic
characterized by the growth of pre-cancerous lesions (or “AKs”). With our national commercial team, we generate revenue by
were formed in 2015 as Biofrontera Inc., a Delaware corporation, and a wholly owned subsidiary of Biofrontera AG, a stock corporation
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $18.8M | $24.1M | $28.7M | $34.1M | $37.3M | $41.7M |
| Net income | -$11.0M | -$37.7M | -$640,000 | -$20.1M | -$17.8M | -$10.5M |
| Free cash flow | — | — | -$16.2M | -$24.9M | -$10.3M | -$13.4M |
More on BFRI.
- Biofrontera Inc. summary
- Biofrontera Inc. financial statements
- Biofrontera Inc. key metrics
- Biofrontera Inc. health scores and style box
- Biofrontera Inc. earnings
- Biofrontera Inc. dividends
- Biofrontera Inc. valuation
- Biofrontera Inc. ownership and insiders
- Biofrontera Inc. peers
Figures from Biofrontera Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.